Pharmaceutical Expenditure as a Determinant of Health Outcomes in EU Countries
DOI:
https://doi.org/10.25115/eea.v31i2.3332Keywords:
Pharmaceutical Expenditure, Health Outcomes, Panel-Data.Abstract
This paper studies the effects that pharmaceutical expenditure and other medical non-durables has on health outcomes, such as mortality and life expectancy. Some recent research is focused on the study of public expenditure in health and the correlation with positive health indicators, and also on the relative effectiveness of various medical health care inputs. As a specific case of this research, we center our interest on the pharmaceutical expenditure among various European countries in order to compare if expenditures are effective in health results, or on the contrary, countries with higher levels of pharmacy consumption do not have better health indicators. We carried out a regression analysis with panel data. The results imply that there is a positive effect between pharmaceutical expenditure and health outcomes.
Downloads
References
AASERUD M., DAHLGREN, A.T., KÖSTERS, J.P., OXMAN, A.D., RAMSAY, C, AND STURM H. (2006): “Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies”. Cochrane Database Systematic Review, 2.
ANAND, S. and RAVALLION, M. (1993): “Human development in poor countries: On the role of private incomes and public services”. The Journal of Economic Perspectives, 7 (1), 133-150.
BABAZONO, A. and HILLMAN, A.L. (1994): “A Comparison of International Health Outcomes and Health Care Spending”. International Journal of Technology Assessment in Health Care, 10, 376-381.
CALISKAN, Z. (2009): “The relationship between pharmaceutical expenditure and life expectancy: evidence from 21 OECD countries”. Applied Economics Letters, 16, 1651-1655.
CANTARERO, D. and PASCUAL, M. (2008): “Analyzing the impact of fiscal decentralization on health outcomes”. Applied Economics Letters, 15, 109- 111.
CEBRIÀ, J., SOBREQUÉ, J., RODRÍGUEZ, C. and SEGURA, J. (2003): “Influencia del desgaste profesional en el gasto farmacéutico de los médicos de atención primaria”. Gaceta Sanitaria, 17 (6), 483-489.
CRÉMIEUX, P.Y., MEILLEUR, M.C., OUELLETTE, P., PETIT, P, ZELDERA, M. and POTVIND, K (2005): “Public and private pharmaceutical spending as determinants of health outcomes in Canada”. Health Economics, 14, 107- 116.
CREMIEUX, P.Y., OUELLETTE, P., MEILLEUR, M.C., LEONG, S. GREENBERG, P. and BIRNBAUM, H. (2001): “Pharmaceutical spending and health outcomes in the United States”. Research in Human Capital and Development, 14, 59-75.
DAY, K. and TOUSIGNANT, J. (2005): “Health Spending, Health Outcomes, and Per Capita Income in Canada: A Dynamic Analysis”. Department of Finance, Working Paper 2005-07.
FILIPPINI, M., GONZÁLEZ ORTIZ, L.G. and MASIERO, G. (2012): "Assessing the impact of national antibiotic campaigns in Europe". European Journal of Health Economics, DOI 10.1007/s10198-012-0404-9.
GARCÍA-SEMPERE, A. and PEIRÓ, S. (2001): “Gasto farmacéutico en atención primaria: variables asociadas y asignación de presupuestos de farmacia por zonas de salud”. Gaceta Sanitaria, 15 (1), 32-40.
GOWRISANKARAN, G. and TOWN, R.J. (2004): “Managed Care, Drug Benefits and Mortality: An Analysis of the Elderly”. NBER Working Paper No. 10204.
GUINDON, G.E. and CONTOYANNIS, P. (2012): “A second look at pharmaceutical spending as determinants of health outcomes in Canada”. Health Economics, 21, 1477-1495.
HAUSMAN, J.A. (1978): “Specification Tests in Econometrics”. Econometrica, 46, 1013-1029.
LIU, L., CLINE, R.R., SCHONDELMEYER, S. W. and SCHOMMER, J. C. (2008): “Pharmaceutical Expenditures as a Correlate of Population Health in Industrialized Nations”. The Annals of Pharmacotherapy, 42(3), 368-74.
MARTIN, S. RICE, N. and SMITH, P.C. (2008): “Does health care spending improve health outcomes? Evidence from English programme budgeting data”. Journal of Health Economics, 27, 826-842.
MORENO-TORRES, I., J. PUIG-JUNOY and J. M. RAYA (2010): “The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain”. European Journal of Health Economics, 12, 563-573.
NAVARRO, J.L. and HERNÁNDEZ, E. (2006): “Health Technologies Assessment: Analysing The Role Of Uncertainty”. Estudios de Economía Aplicada, 24(3), 731-754.
NIXON, J. and ULMANN, P. (2006): “The relationship between health care expenditure and health outcomes. Evidence and caveats for a causal link”. European Journal of Health Economics, 7, 7-18.
OECD (2011), “Pharmaceutical expenditure”, in Health at a Glance 2011: OECD Indicators, OECD Publishing. http://dx.doi.org/10.1787/health_glance- 2011-63-en.
OECD (2012), Health at a Glance: Europe 2012, OECD Publishing. http://dx.doi.org/10.1787/9789264183896-en.
RODRIGUEZ CABERO, G. (2007): “El marco institucional de la protección social de la dependencia en España”. Estudios de Economía Aplicada, 25(2), 341-372.
TOUMI, M., RÉMUZAT, C. and CREATIV-CEUTICAL (2012): “EU Pharmaceutical expenditure forecast”, Executive Agency for Health and ConsumersEAHC-European Commission (DG SANCO), forthcoming.
VOGLER, S. ZIMMERMANN, N.,LEOPOLD, C. and DE JONCHEERE, K. (2011); “Pharmaceutical policies in European countries in response to the global financial crisis” Southern Medical Review, 4(2), 69-79.
WOLFE, B. (1986): “Health status and medical expenditures: Is there a link?” Social Science & Medicine, 22(10), 993-999.
WOLFE, B. and GABAY, M. (1987): “Health status and medical expenditures: More evidence of a link”. Social Science & Medicine, 25(8), 883-888.
ZEYNEP OR (2000): “Determinants of health outcomes in industrialised countries: a pooled, cross-country, time-series analysis”. OECD Economic Studies No. 30, 2000/I.
